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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major nosocomial
pathogens. Due to the diffusion of MRSA strains in both hospital and community settings,
prevention and control strategies are receiving increased attention. Approximately 25% to 30% of
the population is colonised with S. aureus and 0.2% to 7% with MRSA. The BD GeneOhm MRSA
real-time PCR assay offers quicker identification of MRSA-colonised patients than do culture
methods.
Methods: Ninety-five patients admitted to the Intensive Care Unit of IRCCS Policlinico San
Matteo of Pavia (Italy) for a period > 24 h were screened for MRSA colonisation with both the
culture method and the GeneOhm assay.
Results: Of the 246 nasal swabs collected from 95 patients, 36 samples were found to be positive
by both methods (true-positive). 30% of colonised patients had developed the MRSA infection.
Conclusion: Our results show that the GeneOhm MRSA assay is a valuable diagnostic tool for
detecting MRSA quickly in nasal swabs. This study confirms that colonisation represents a high risk
factor for MRSA infection, and that good MRSA surveillance in an Intensive Care Unit is therefore
an excellent way to prevent MRSA infection.
Background
Methicillin-resistant  Staphylococcus aureus (MRSA) is a
nosocomial pathogen that is conspicuously responsible
for increased morbidity and mortality, as well as for pro-
longed hospitalization. As such, it substantially increases
hospital and health system costs [1,2].
MRSA originates from the introduction of a large mobile
genetic element called staphylococcal cassette chromo-
some  mec  (SCC  mec) into a methicillin-susceptible S.
aureus  strain. Methicillin-resistance is conferred by the
mecA gene, which encodes a penicillin-binding protein
(PBP2A) with decreased affinity for β-lactam antibiotics,
and which forms part of the mobile genetic element [3].
MRSA infections have recently become the focus of
intense media attention. In 2005, the United States press
described MRSA as the "super bug", on the basis that it
killed more people than did AIDS [4]. Due to the diffu-
sion of MRSA in both hospital and community settings,
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prevention and control strategies are receiving increased
attention. Multiple infection control practices, including
hand hygiene, identification of MRSA carriers, patient-
decolonization, and environmental decontamination, are
used in combination to prevent nosocomial infections.
Contact isolation of MRSA carriers also prevents transmis-
sion within the hospital [5].
Approximately 25% to 30% of the population is colo-
nised with S. aureus and 0.2% to 7% with MRSA; conse-
quently, not only infected patients, but also colonised
patients, represent the most important reservoir of MRSA
in health-care facilities. Nasal MRSA colonisation can
serve as a source for transmission and is also considered a
risk factor for subsequent infection [6]. Consequently,
periodic nasal swab collection contributes positively to
the containment of MRSA in high risk areas.
The combined use of surveillance cultures and barrier pre-
cautions produces cost savings for hospitals. The cost of
caring for MRSA-infected patients greatly exceed that of
screening programmes.
Because it is more sensitive than culture methods, PCR
identifies MRSA-colonised patients more quickly [7]. Cul-
ture-based detection of MRSA with traditional media
requires 48 to 96 h for results. In contrast, new real-time
PCR-based methods allow differentiation of methicillin-
sensitive Staphylococcus aureus (MSSA), MRSA, and coagu-
lase-negative Staphylococci within a few hours [8-11].
Such tests promote an early appropriate antibiotic selec-
tion, and they reduce mortality, the length of hospitaliza-
tion, and the costs associated with infections caused by
these bacteria [12]. Furthermore, the BD GeneOhm MRSA
real-time PCR assay, formerly called the IDI-MRSA assay
(BD Diagnostics, San Diego, CA), identifies MRSA-colo-
nised patients in as little as 2 h [9]. This multiplex real-
time PCR amplifies an S. aureus-specific target sequence
near the staphylococcal cassette chromosome mec (SCC
mec) insertion site and the orfX junction in MRSA, and
thereby differentiates between MSSA and MRSA [9,11].
We evaluated the diagnostic performance of the Gene-
Ohm MRSA assay for the detection of MRSA from nasal
swab from patients hospitalized in an Intensive Care Unit.
Methods
Patients
The study period was from 10th July to 23rd October 2007.
The "Servizio di Anestesia e Rianimazione I" of the IRCCS
Policlinico San Matteo, Pavia, is one of the hospital's two
general Intensive Care Units. The unit in question com-
prises 10 sleeping accommodations and usually admits
about 450 patients yearly. More than half of the popula-
tion are surgical patients; about 30% are admitted from
medical wards within the hospital or from the emergency
room for non-surgical reasons or on account of trauma.
The unit isolates patients upon MRSA identification
because even more MRSA colonisation without infection
can serve as an MRSA source and hence endanger other
patients. MRSA-colonised patients without infection are
not subjected to antibiotic or colonisation therapy.
Ninety-five patients admitted to the Intensive Care Unit of
IRCCS Policlinico San Matteo, Pavia, for a period > 24 h
were screened for MRSA colonisation. Nasal swab collec-
tion was performed upon admission and twice-weekly
thereafter. The swab was introduced into the anterior nare
and rotated five times. Then the nasal swab was inserted
into a tube containing 1 ml Tryptic Soy Broth (TSB,
Oxoid) with NaCl 6.5%. The specimens were transported
at room temperature and processed with culture and
molecular methods.
Culture methods
All isolates were processed by standard laboratory meth-
ods. The nasal swab was used to directly streack (about
100 μl) the samples onto Mannitol-salt-agar (Biomerieux)
and Columbia blood agar (Biomerieux). The plates were
incubated at 35°C for 24–48 h. A putative MRSA colony
was confirmed by Gram stain, catalase test, and tube coag-
ulase. Methicillin-resistance was tested by means both of
Mueller-Hinton agar containing 6 mg/l oxacillin and 4%
NaCl, and of the cefoxitin disk diffusion method, in
accordance with the CLSI protocol [13].
Real-time procedure
The swabs were also processed with the real-time PCR-
based BD GeneOhm MRSA Assay (Becton Dickinson
Diagnostics), in accordance with the manufacturer's
instructions. Our use of exclusively nasal swabs was deter-
mined by the manufacturer's recommendation and by the
fact that the nostrils are indeed the main site of S. aureus
colonization.
The procedure was very easy: the nasal swab was placed in
a tube with the buffer, and the resulting suspension was
transferred to a lysis tube for DNA extraction. Subsequent
addition of kit's molecular reagents was followed by real-
time PCR. The entire process run-time was about 2 hours.
A positive control (supplied with the kit) and a negative
control (reaction without template) were included in each
run.
Data analysis
GeneOhm MRSA results were compared with those
obtained from the culture method. A sample found to be
positive under both GeneOhm assay and the cultureBMC Infectious Diseases 2009, 9:137 http://www.biomedcentral.com/1471-2334/9/137
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method was defined a true-positive result. A true-negative
result was one that proved negative under both methods.
A sample that was positive under GeneOhm assay and
negative under culture method was defined as false-posi-
tive.
The per sample cost of the molecular method was approx-
imately € 40. Calculated from multiple applications, this
figure is an average, and takes into account the kit rea-
gents, the consumable materials, and the kit controls
(positive and negative), which were invariably processed
with each sample. The procedure time for this method
was about 2 hours.
The culture method cost about € 4, a figure that com-
prised the use of selective plates, biochemical tests, and
consumable materials. Procedure time was 36–48 hours.
The study procedure was approved by IRCCS Policlinico
San Matteo, Pavia, Italy.
Results and discussion
Ninety-five patients admitted to the Intensive Care Unit
(I) of IRCCS Policlinico San Matteo of Pavia from 10th of
July to 23rd of October 2007 for a period > 24 h were
screened for MRSA colonisation. Altogether, 246 nasal
swabs from 95 patients were processed by both the molec-
ular and the culture methods. Forty seven patients were
hospitalised for a period < 3 days and underwent nasal
swab only once; 17 patients were nasally swabbed twice,
9 patients three times, and 22 patients 4 or more times.
MRSA detection by culture method
A total of 246 nasal swabs were processed with the culture
method, as described above. Only 36 samples were posi-
tive for MRSA colonisation (14.6%).
MRSA finding by GeneOhm assay and comparison with 
culture method
During our study, 246 nasal swabs from 95 ICU patients
were tested using PCR and conventional methods. Table 1
shows fifty-six nasal swabs as positive for MRSA colonisa-
tion under GeneOhm assay (22.76% of the total 246
nasal swabs performed).
Of these, 36 samples (14.6%) were positive under culture
method (true-positive), while 20 (8.8%) were positive
under GeneOhm assay and negative under culture
method (false-positive).
Within the false-positive group, 5 patients yielded only a
single nasal swab either because they died in, or were
transferred from the hospital. A further 12 false-positive
results derived from 3 patients that had previously been
found to be positive to MRSA colonisation under culture
method. Arguably, the false-positive MRSA colonisation
status of these patients could be due to the molecular
method's greater sensitivity to what could have been very
low bacterial concentrations. In other words, it is possible
that some or all of the given 12 false-positive were in fact
true-positive results.
In the present study, GeneOhm™ MRSA assay gave no
false-negative, and only 20 false-positive results. A total
190 (77.23%) samples were found to be negative under
both methods. Thirteen cases (5.2%) were not resolved by
GeneOhm assay, but proved to be positive under repeated
assay.
Agreement between the molecular and culture methods
was 91.8% (226/246). Comparatively, GeneOhm assay
was significantly more sensitive than the culture method:
the former demonstrated sensitivity of 100% (36/36) and
specificity of 90,4% (190/210). Our choice of collecting
exclusively nasal swabs was based on the fact that the
anterior nare is the primary basin for S. aureus. Previous
studies [7,14] have shown that nose-only specimens are
90% sensitivity for MRSA-detection purposes, while com-
bined nose and groin samples are 88% sensitive, and skin
or other superficial sites 76.5%. Exclusively nasal sam-
pling would appear to be adequate. Moreover, our data
indicated that nasal surveillance captured 100% of MRSA
colonisation, a finding which enhances the case for this
method as a sound basis for MRSA detection.
As shown in previous studies and in this work, BD Gene-
Ohm™ MRSA assay is both specific and sensitive [1,10,14-
17]. Similar results regarding the sensitivity of the Gene-
Ohm™ MRSA assay for single throat swabs have already
been described by Rossney et al. (2007) [16] (89.0% sen-
sitivity and 99.0% specificity) and van Hal et al. (2007)
[17] (90.0% sensitivity and 96.0% specificity). In a recent
study by Svent-Kucina et al. (2009) [11], the GeneOhm™
MRSA assay protocol was modified during the specimen
preparation step by the addition of an extra washing step,
followed by the pooling of up to 3 samples per patient
(nose, skin, with or without throat) at the lysis step. The
Table 1: Comparison between results obtained by the culture 
and molecular methods
Gene Ohm assay Culture method
Positive Negative Total
Positive 36 20 56
Negative 0 190 190
Total 36 210 246BMC Infectious Diseases 2009, 9:137 http://www.biomedcentral.com/1471-2334/9/137
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sensitivity and specificity rates of the modified assay in
comparison with those of conventional culture were
respectively 94.3% and 99.2%.
In a recent study, Boyce et al. (2008) [18] compared the
GeneOhm MRSA assay with the CHROMagar MRSA assay
(BD Diagnostics) for the detection of MRSA in 286 nasal
surveillance specimens; the GeneOhm assay proved to be
both faster and more sensitive.
All these examples agree with our results on the sensitivity
and specificity of the molecular method utilised.
Infection rate versus colonisation rate
Ten patients were true-positive under both methods; 2 of
them were MRSA carriers on admission, while 8 were col-
onised in ICU: 3 patients after 4 days, 4 after 5–7 days and
1 after 30 days. The colonisation rate was 10.5% (10/95),
but it increases to 16.8% (16/95) if we add 6 false-positive
patients that were MRSA carriers on admission. All 10
patients were isolated upon MRSA identification.
Only 3 (30%) MRSA colonised patients developed MRSA
infection. Specifically, after 7 days of colonisation, 2
patients respectively showed an MRSA infection from a
surgical wound, and pneumonia; after 10 days of coloni-
sation, the 3rd patient developed central venous catheter-
related sepsis.
Disadvantages and benefits of the molecular method
The molecular assay here described is performed directly
from the sample (e.g. nasal swab). Previous real-time PCR
assays have demonstrated a capacity to detect MRSA rap-
idly in culture [9]. Reischl et al. (2000) [19] reported a
duplex assay for mecA  and the S. aureus-specific  sa442
genome. They reported 100% sensitivity and specificity
for the detection of MRSA in "pure colonies". The critical
advantage offered by the GeneOhm MRSA assay is that it
circumvents pure colony isolation and thus enables direct
use of specimens.
However, none of the assays described before [9,19] was
able to differentiate methicillin-resistant S. aureus from
methicillin-resistant coagulase negative Staphylococcus
spp. in primary specimens that simultaneously host both
of these organisms, such as occurs in anterior nares speci-
mens. In the GeneOhm assay, the use of primer sequences
for the SCCmec and orfX regions generates an MRSA-spe-
cific amplicon, which in turn is detected by a complemen-
tary molecular beacon probe.
Reliable and rapid detection of MRSA-colonised patients
is essential for the successful prevention and control of
MRSA outbreaks in hospital, and hence for overall patient
care and hospital infection control. The BD GeneOhm™
MRSA assay's speed (amplification time of 2 h versus 36–
48 h for the culture method) gives it a critical advantage.
Timely identification of MRSA colonisation allows the
isolation and treatment of affected patients and thus is
essential for the prevention of MRSA outbreaks. Cunning-
ham et al. (2007) [20] demonstrated a reduction in MRSA
transmission incidence from 13.9/1,000 patient days
under phenotypic (culture-based) MRSA surveillance to
4.9/1,000 patient days under PCR screening.
MRSA prevalence and incidence within an institution are
the major determinants of the number of patients that
need to be screened in order to prevent one infection.
Molecular methods cost approximately 10 times more per
test than conventional methods (€ 40 versus € 4), and
infection control programs remain poorly resourced.
However, rapid screening is able to save on patient pre-
ventive isolation costs (if instituted) and on costs associ-
ated with the prevention of hospital-acquired MRSA
infections [21].
Further research into the cost effectiveness of molecular
testing is needed.
Conclusion
The growing threat of MRSA is increasingly apparent both
to the public and to health care providers. MRSA infec-
tions are yet another major factor in the current spiralling
of health care costs. It is imperative that clinicians have a
high index of suspicion for MRSA so that the initiation of
the appropriate antibiotic therapy is prompt [1].
Our results with the GeneOhm MRSA assay show that it is
an accurate and rapid way to detect MRSA colonisation.
This assay can be performed by a microbiologist techni-
cian with minimal additional training and allows same-
day results.
This study also confirms that colonisation is a high risk
factor for MRSA infection, and consequently that good
MRSA surveillance in an Intensive Care Unit is an excel-
lent way to prevent MRSA infection.
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